Current radiopharmaceuticals最新文献

{"title":"Design of a New ^99mTc-radiolabeled Cyclo-peptide as Promising Molecular Imaging Agent of CXCR₄ Receptor: Molecular Docking, Synthesis, Radiolabeling, and Biological Evaluation.","authors":"Leila Hassanzadeh, Mostafa Erfani, Safura Jokar, Marjan Shariatpanahi","doi":"10.2174/0118744710249305231017073022","DOIUrl":"10.2174/0118744710249305231017073022","url":null,"abstract":"<p><strong>Introduction: </strong>C-X-C Chemokine receptor type 4 (CXCR4) is often overexpressed or overactivated in different types and stages of cancer disease. Therefore, it is considered a promising target for imaging and early detection of primary tumors and metastasis. In the present research, a new cyclo-peptide radiolabelled with ^99mTc, ^99mTc-Cyclo [D-Phe-D-Tyr-Lys (HYNIC)- D-Arg-2-Nal-Gly-Lys(iPr)], was designed based on the parental LY251029 peptide, as a potential <i>in vivo</i> imaging agent of CXCR4-expressing tumors.</p><p><strong>Methods: </strong>The radioligand was successfully prepared using the method of Fmoc solid-phase peptide synthesis and was evaluated in biological assessment. Molecular docking findings revealed high affinity (binding energy of -9.7 kcal/mol) and effective interaction of Cyclo [D-Phe- D-Tyr-Lys (HYNIC)-D-Arg-2-Nal-Gly-Lys(iPr)] in the binding pocket of CXCR4 receptor (PDB code: 3OE0) as well.</p><p><strong>Result: </strong>The synthesized peptide and its purity were assessed by both reversed-phase high-performance liquid chromatography (RP-HPLC) and mass spectroscopy. High stability (95%, n = 3) in human serum and favorable affinity (Kd = 28.70 ± 13.56 nM and Bmax = 1.896 ± 0.123 fmol/mg protein) in the B16-F10 cell line resulted. Biodistribution evaluation findings and planar image interpretation of mice both showed high affinity and selectivity of the radiotracer to the CXCR4 receptors.</p><p><strong>Conclusion: </strong>Therefore, the findings indicate this designed radioligand could be used as a potential SPECT imaging agent in highly proliferated CXCR4 receptor tumors.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":" ","pages":"77-90"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71421605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Radioprotective Effect of LBP on Neurogenesis and Cognition after Acute Radiation Exposure.","authors":"Gang Yin, Qinqi Wang, Tongtong Lv, Yifan Liu, Xiaochun Peng, Xianqin Zeng, Jiangrong Huang","doi":"10.2174/0118744710274008231220055033","DOIUrl":"10.2174/0118744710274008231220055033","url":null,"abstract":"<p><strong>Background: </strong>Radiation exposure has been linked to the development of brain damage and cognitive impairment, but the protective effect and mechanism of Lycium barbarum pills (LBP) on radiation-induced neurological damage remains to be clarified.</p><p><strong>Methods: </strong>Behavioral tests and immunohistochemical studies were conducted to evaluate the protective effects of LBP extract (10 g/kg orally daily for 4 weeks) against radiation-induced damage on neurogenesis and cognitive function in Balb/c mice exposed to 5.5 Gy X-ray acute radiation.</p><p><strong>Results: </strong>The results showed that the LBP extract significantly improved body weight loss, locomotor activity and spatial learning and memory. Immunohistochemical tests revealed that the LBP extract prevented the loss of proliferating cells, newly generated neurons and interneurons, especially in the subgranular area of the dentate gyrus.</p><p><strong>Conclusion: </strong>The findings suggest that LBP is a potential neuroprotective drug for mitigating radiation-induced neuropsychological disorders.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":" ","pages":"257-265"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11327742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139416639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"One Method to Label Them All\": A Single Fully Automated Protocol for GMP-Compliant ⁶⁸Ga Radiolabeling of PSMA-11, Transposable to PSMA-I&T and PSMA-617.","authors":"Juliette Fouillet, Charlotte Donzé, Emmanuel Deshayes, Lore Santoro, Léa Rubira, Cyril Fersing","doi":"10.2174/0118744710293461240219111852","DOIUrl":"10.2174/0118744710293461240219111852","url":null,"abstract":"<p><strong>Background: </strong>Prostate-specific membrane antigen (PSMA) is an ideal target for molecular imaging and targeted radionuclide therapy in prostate cancer. Consequently, various PSMA ligands were developed. Some of these molecules are functionalized with a chelator that can host radiometals, such as ⁶⁸Ga for PET imaging. The ⁶⁸Ga radiolabeling step benefits from process automation, making it more robust and reducing radiation exposure.</p><p><strong>Objective: </strong>To design a single automated radiolabeling protocol for the GMP-compliant preparation of [⁶⁸Ga]Ga-PSMA-11, transposable to the production of [⁶⁸Ga]Ga-PSMA-617 and [⁶⁸Ga]Ga-PSMA-I&T.</p><p><strong>Methods: </strong>A GAIA^® synthesis module and a GALLIAD^® generator were used. Radio-TLC and radio-HPLC methods were validated for radiochemical purity (RCP) determination. Three [⁶⁸Ga]Ga-PSMA-11 validation batches were produced and thoroughly tested for appearance and pH, radionuclide identity and purity, RCP, stability, residual solvent and sterility. Minimal modifications were made to the reagents and disposables for optimal application to other PSMA ligands.</p><p><strong>Results: </strong>[⁶⁸Ga]Ga-PSMA-11 for clinical application was produced in 27 min. The 3 validation batches met the quality criteria expected by the European Pharmacopoeia to allow routine production. For optimal transposition to PSMA-617, the solid phase extraction cartridge was changed to improve purification of the radiolabeled product. For application to PSMA-I&T, the buffer solution initially used was replaced by HEPES 2.7 M to achieve good radiochemical yields. Residual HEPES content was checked in the final product and was below the Ph. Eur. threshold.</p><p><strong>Conclusion: </strong>A single automated radiolabeling method on the GAIA^® module was developed and implemented for ⁶⁸Ga radiolabeling of 3 PSMA ligands, with slight adjustments for each molecule.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":" ","pages":"285-301"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139995834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exposure to Low-Frequency Radiation Changes the Expression of Nestin, VEGF, BCRP and Apoptosis Markers During Glioma Treatment Strategy: An In Vitro Study","authors":"Maryam Amirinejad, Seyed Hassan Eftekhar-Vaghefi, Seyed Noureddin Nematollahi-Mahani, Moein Salari, Rasoul Yahyapour, Meysam Ahmadi-Zeidabadi","doi":"10.2174/0118744710258350230921065159","DOIUrl":"https://doi.org/10.2174/0118744710258350230921065159","url":null,"abstract":"Background: Exposure to physical contamination during chemotherapy, including non-ionizing electromagnetic field, raising concerns about the widespread sources of exposure to this type of radiation. Glioblastoma multiform (GBM) is an aggressive tumor of the central nervous system that is hard to treat due to resistance to drugs such as temozolomide (TMZ). Objective: Electromagnetic fields (EMF) and haloperidol (HLP) may have anticancer effects. In this study, we investigated the effects of TMZ, HLP, and EMF on GBM cell lines and analyzed the association between non-ionizing radiation and the risk of change in drug performance. Methods: Cell viability and reactive oxygen species (ROS) generation were measured by MTT and NBT assay, respectively. Then, the expression levels of breast cancer-resistant protein (BCRP), Bax, Bcl2, Nestin, vascular endothelial growth factor (VEGF) genes, and P53, Bax, and Bcl2 Proteins were evaluated by real-time PCR and western blot. Results: Co-treatment of GBM cells by HLP and TMZ enhanced apoptosis in T-98G and A172 cells by increasing the expression of P53 and Bax and decreasing Bcl-2. Interestingly, exposure of GBM cells to EMF decreased apoptosis in the TMZ+HLP group. Conclusion: In conclusion, EMF reduced the synergistic effect of TMZ and HLP. This hypothesis that patients who are treated for brain tumors and suffer from depression should not be exposed to EMF is proposed in the present study. There appears to be an urgent need to reconsider exposure limits for low-frequency magnetic fields, based on experimental and epidemiological research, the relationship between exposure to non-ionizing radiation and adverse human health effects.","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135647546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Computed Tomography-based Radiomics Analysis of Low-energy Proximal Femur Fractures in the Elderly Patients.","authors":"Seyed Mohammad Mohammadi,&nbsp;Samir Moniri,&nbsp;Payam Mohammadhoseini,&nbsp;Mohammad Ghasem Hanafi,&nbsp;Maryam Farasat,&nbsp;Mohsen Cheki","doi":"10.2174/1874471016666230321120941","DOIUrl":"https://doi.org/10.2174/1874471016666230321120941","url":null,"abstract":"<p><strong>Introduction: </strong>Low-energy proximal femur fractures in elderly patients result from factors, like osteoporosis and falls. These fractures impose high rates of economic and social costs. In this study, we aimed to build predictive models by applying machine learning (ML) methods on radiomics features to predict low-energy proximal femur fractures.</p><p><strong>Methods: </strong>Computed tomography scans of 40 patients (mean ± standard deviation of age = 71 ± 6) with low-energy proximal femur fractures (before a fracture occurs) and 40 individuals (mean ± standard deviation of age = 73 ± 7) as a control group were included. The regions of interest, including neck, trochanteric, and intertrochanteric, were drawn manually. The combinations of 25 classification methods and 8 feature selection methods were applied to radiomics features extracted from ROIs. Accuracy and the area under the receiver operator characteristic curve (AUC) were used to assess ML models' performance.</p><p><strong>Results: </strong>AUC and accuracy values ranged from 0.408 to 1 and 0.697 to 1, respectively. Three classification methods, including multilayer perceptron (MLP), sequential minimal optimization (SMO), and stochastic gradient descent (SGD), in combination with the feature selection method, SVM attribute evaluation (SAE), exhibited the highest performance in the neck (AUC = 0.999, 0.971 and 0.971, respectively; accuracy = 0.988, 0.988, and 0.988, respectively) and the trochanteric (AUC = 1, 1 and 1, respectively; accuracy = 1, 1 and 1, respectively) regions. The same methods demonstrated the highest performance for the combination of the 3 ROIs' features (AUC = 1, 1 and 1, respectively; accuracy =1, 1 and 1, respectively). In the intertrochanteric region, the combination methods, MLP + SAE, SMO + SAE, and SGD + SAE, as well as the combination of the SAE method and logistic regression (LR) classification method exhibited the highest performance (AUC = 1, 1, 1 and 1, respectively; accuracy= 1, 1, 1 and 1, respectively).</p><p><strong>Conclusion: </strong>Applying machine learning methods to radiomics features is a powerful tool to predict low-energy proximal femur fractures. The results of this study can be verified by conducting more research on bigger datasets.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":"16 3","pages":"222-232"},"PeriodicalIF":2.3,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9592629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac Injury Following Chemo/Radiation Therapy: An Updated Review on Mechanisms and Therapeutic Approaches.","authors":"Krishanveer Singh,&nbsp;Ameer A Alameri,&nbsp;Ammar Ali Hamza,&nbsp;Moaed E Al-Gazally,&nbsp;Sarvar Temurovich Islomov,&nbsp;Rasha Fadhel Obaid,&nbsp;Andrés Alexis Ramírez-Coronel,&nbsp;Munther Abosaooda,&nbsp;Rasoul Yahyapour,&nbsp;Masoud Najafi","doi":"10.2174/1874471016666230214101830","DOIUrl":"https://doi.org/10.2174/1874471016666230214101830","url":null,"abstract":"<p><p>Cardiovascular disorders are among the critical side effects of cancer therapy. Damage to the function and normal structure of the heart can cause serious threats to patients that are being treated for cancer. Cardiovascular complications may be induced by various types of chemotherapy drugs and also radiation therapy. The severity of cardiovascular toxicity depends on several factors, such as types of drugs, tumor location for radiotherapy, the presence of cardiac disease history, the dose of drugs or ionizing radiation, etc. Radiotherapy and chemotherapy can cause heart diseases through various mechanisms, such as oxidative stress, inflammation, cell death, fibrosis, endothelial to mesenchymal transition (EndMT), etc. Chronic inflammation following damage to a huge number of cells can trigger more accumulation of inflammatory cells and chronic release of reactive oxygen species (ROS) and nitric oxide (NO). Oxidative stress can induce more cell death and cardiac remodeling through damage to vessels and valvular and disruption of the normal structure of the extracellular matrix. These changes may lead to cardiomyopathy, myocarditis, pericarditis, and vascular disorders that may lead to heart attack and death. This review provides basic information on cellular and molecular mechanisms of different types of cardiovascular disorders following cancer therapy by radiation or chemotherapy. We also recommend some adjuvants and targets to reduce the risk of heart toxicity by radiation/chemotherapy.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":"16 3","pages":"185-203"},"PeriodicalIF":2.3,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9960390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DTPA(DOTA)-Nimotuzumab Radiolabeling with Generator-produced Thorium for Radioimmunotherapy of EGFR-overexpressing Carcinomas.","authors":"Magdiel G Bravo, Bayirta V Egorova, Aleksandr N Vasiliev, Elena V Lapshina, Stanislav V Ermolaev, Mikhail O Durymanov","doi":"10.2174/1874471016666230221102518","DOIUrl":"10.2174/1874471016666230221102518","url":null,"abstract":"<p><strong>Introduction: </strong>The feasibility of preparing the \"in-house\" generators and the Th- DTPA(DOTA)-Nimotuzumab radioimmunoconjugate was evaluated. ²²⁶Th is perspective for TAT, however, due to short half-life it is preferable to apply this radionuclide for readily available epithelial malignancies. Nimotuzumab being specific for EGFR expressing cells as a targeting moiety is considered to be suitable for thorium delivery.</p><p><strong>Methods: </strong>TEVA extraction chromatographic resin and anion exchange resin AG 1x8 were used as sorbents for ²²⁶Th generator. In order to determine features of labeling by Th4⁺ we applied ²³⁴Th as a longer-lived analog of short-lived ²²⁶Th and the immunoconjugates DTPA(DOTA)-Nimotuzumab were used for radiolabeling.</p><p><strong>Results: </strong>The generator on the base of TEVA resin has shown higher volume activity of the product compared to the AG 1x8. The ²²⁶Th volume concentration was up to 80%/mL. The radiolabeling of BFCA by thorium radioisotopes reached 95% at the MR(Th:p-SCN-Bn-DTPA) = 1:100 and 86% for MR(Th:p-SCN-Bn-DOTA) = 1:5000 at 90°C. The procedure of Nimotuzumab labeling with Th4+ for radiotherapy of EGFR-overexpressing carcinomas was established. The overall labeling yield in both radioimmunoconjugates - DTPA and DOTA functionalized - was in the range of 45-50%. The immunoconjugate Nimotuzumab-p-SCN-Bn-DTPA was obtained with a molar ratio 1:25 (Nimotuzumab: BFCA), within 1 hour of conjugation at 25°C and labelled <i>via</i> postconjugation approach. Whereas Nimotuzumab-p-SCN-Bn-DOTA was obtained at the same conditions, but radiolabeled by the method of pre-conjugation.</p><p><strong>Conclusion: </strong>Thorium-234 incorporation into both radioimmunoconjugates reached 45-50%. It has been shown that Th-DTPA-Nimotuzumab radioimmunoconjugate specifically bound with EGFR overexpressing epidermoid carcinoma A431 cells.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":"16 3","pages":"233-242"},"PeriodicalIF":2.3,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9642012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Promising Radiopharmaceutical Tracers for Detection of Cardiotoxicity in Cardio-oncology.","authors":"Zahra Shaghaghi,&nbsp;Fatemeh Jalali Zefrei,&nbsp;Arsalan Salari,&nbsp;Seyed Amineh Hojjati,&nbsp;Seyed Aboozar Fakhr Mousavi,&nbsp;Soghra Farzipour","doi":"10.2174/1874471016666230228102231","DOIUrl":"https://doi.org/10.2174/1874471016666230228102231","url":null,"abstract":"<p><p>Cancer treatment has the potential to cause cardiovascular issues and can encourage the appearance of all aspects of cardiac disease, including coronary heart disease, myocardial disease, heart failure, structural heart disease, and rhythm problems. Imaging is required for both diagnostic workup and therapy monitoring for all possible cardiovascular side effects of cancer therapy. Echocardiography is the cardiac imaging gold standard in cardio-oncology. Despite advancements in its use, this method is often not sensitive to early-stage or subclinical impairment. The use of molecular imaging technologies for diagnosing, assessing, and tracking cardiovascular illness as well as for treating, it is fast growing. Molecular imaging techniques using biologically targeted markers are gradually replacing the traditional anatomical or physiological approaches. They offer unique insight into patho-biological processes at the molecular and cellular levels and enable the evaluation and treatment of cardiovascular disease. This review paper will describe molecularbased single-photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging techniques that are now available and in development to assess post-infarction cardiac remodeling. These methods could be used to evaluate important biological processes such as inflammation, angiogenesis, and scar formation.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":"16 3","pages":"171-184"},"PeriodicalIF":2.3,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9960885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gamma Knife Radiosurgery Modulates micro-RNA Levels in Patients with Brain Metastasis.","authors":"Imran Khan,&nbsp;Kerime Akdur,&nbsp;Sadaf Mahfooz,&nbsp;Elif Burce Elbasan,&nbsp;Ayten Sakarcan,&nbsp;Busra Karacam,&nbsp;Georges Sinclair,&nbsp;Sahabettin Selek,&nbsp;Fahri Akbas,&nbsp;Mustafa Aziz Hatiboglu","doi":"10.2174/1874471016666230202164557","DOIUrl":"https://doi.org/10.2174/1874471016666230202164557","url":null,"abstract":"<p><strong>Background: </strong>The relation between micro-RNA (miRNA) modulation and immune cell activity in high-dose radiation settings is not clearly understood.</p><p><strong>Objective: </strong>To investigate the role of stereotactic radiosurgery (SRS) in (i) the regulation of tumorsuppressor and oncogenic miRNAs as well as (ii) its effect on specific immune cell subsets in patients with metastatic brain tumors (MBT).</p><p><strong>Methods: </strong>9 MBT patients who underwent gamma knife-based stereotactic radiosurgery (GKRS) and 8 healthy individuals were included. Serum samples were isolated at three-time intervals (before GKRS, 1 hour, and 1-month post-GKRS). Expressions of tumor-suppressor (miR-124) and oncogenic (miR-21, miR-181a, miR-23a, miR-125b, and miR-17) miRNAs were quantified by qPCR. The lymphocytic frequency (CD3⁺, CD4⁺, CD8^+, CD56⁺, CD19⁺, and CD16⁺) was investigated by means of flow cytometry.</p><p><strong>Results: </strong>The median age was 64 years (range: 50-73 years). The median prescription dose was 20Gy (range: 16Gy-24Gy), all delivered in a single fraction. The median overall survival and progression- free survival were 7.8 months (range: 1.7-14.9 months) and 6.7 months (range: 1.1-11.5 months), respectively. Compared to healthy controls, baseline levels of oncogenic miRNAs were significantly higher, while tumor-suppressing miRNA levels remained markedly lower in MBT patients prior to GKRS. Following GKRS, there was a reduction in the expression of miR-21, miR-17, and miR-181a; simultaneously, increased expression increased of miR-124 was observed. No significant difference in immune cell subsets was noted post GKRSIn a similar fashion. We noted no correlation between patient characteristics, radiosurgery data, miRNA expression, and immune cell frequency.</p><p><strong>Conclusion: </strong>For this specific population with MBT disease, our data suggest that stereotactic radiosurgery may modulate the expression of circulating tumor-suppressor and oncogenic miRNAs, ultimately enhancing key anti-tumoral responses. Further evaluation with larger cohorts is warranted.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":"16 3","pages":"204-213"},"PeriodicalIF":2.3,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9580010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An In-House 3D Voxel Dosimetric Tool to Compare Predictive and Post- Treatment Dosimetry in ⁹⁰Y Radioembolization: A Proof of Concept.","authors":"Ornella Ferrando,&nbsp;Rossana Bampi,&nbsp;Franca Foppiano,&nbsp;Andrea Ciarmiello","doi":"10.2174/1874471016666230215102455","DOIUrl":"https://doi.org/10.2174/1874471016666230215102455","url":null,"abstract":"<p><strong>Aim: </strong>The aim of this study was to implement an in-house dosimetric tool to assess tumour- absorbed doses in pre and post-dosimetry for ⁹⁰Y radioembolization with resin spheres.</p><p><strong>Materials and methods: </strong>To perform dosimetric calculations we set up a dosimetric procedure and developed homemade software to calculate tumour absorbed dose and dose volume histograms (DVHs). The method is based on a simplified voxel dosimetry for an estimated 3D absorbed dose and it can be applied to both ^99mTc-MAA SPECT/CT and ⁹⁰Y PET/CT acquisitions for pre and post-dosimetry. We tested the software performance in a retrospective study using the data of 22 patients with hepatocellular carcinoma who underwent radioembolization with ⁹⁰Y resin spheres in the period 2016-2021. The software calculates tumour doses (mean, minimum and maximum doses) from voxel counts and dose-volume histograms (DVH_spect, DVH_pet) for both ^99mTc-MAA SPECT/CT and ⁹⁰Y PET/CT imaging. DVH_spect and DVH_pet data were analyzed and compared with the aim to assess an agreement between them. Concordance between dosimetric data were evaluated with the Wilcoxon Signed Ranked test, descriptive statistical analysis and Pearson correlation coefficient.</p><p><strong>Results: </strong>The mean administrated activity was 1313 MBq (range 444 MBq - 2200 MBq). Tumour volumes ranged from 75 mL to 1012 mL. The mean absorbed dose for tumour volume was 161 ± 66 Gy (Dm_spect) and 173 ± 79 Gy (Dm_pet). From Wilcoxon Signed Rank Test the differences between the dosimetric data extrapolated from DVH_spect and DVH_pet results were not significant with α = 0.05 (two-sided test). A good linear correlation was found between ^99mTc-MAA and ⁹⁰Y dosimetric data (Pearson correlation coefficient 0.887 p < 0.001). Generally, DVHs calculated on ^99mTc-MAA SPECT/CT and ⁹⁰Y PET/CT gave comparable results, some discrepancies were observed particularly with those patients where SPECT and PET imaging presented a visual mismatching.</p><p><strong>Conclusion: </strong>A simplified 3D dosimetry methodology was implemented and tested retrospectively on patient data treated with ⁹⁰Y resin spheres. Even if the clinical feasibility of our approach has to be further validated on an extended patient cohort, the preliminary results of our study highlight the potential of the implemented dosimetric tool for tumour dose assessment.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":"16 3","pages":"214-221"},"PeriodicalIF":2.3,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9642008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}